Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA4 | P22748 | 5/20 | 0.44 |
| ▸ | CA12 | O43570 | 4/20 | 0.44 |
| ▸ | CA1 | P00915 | 3/20 | 0.44 |
| ▸ | CA2 | P00918 | 3/20 | 0.44 |
| ▸ | CA9 | Q16790 | 3/20 | 0.44 |
| ▸ | MTNR1A | P48039 | 5/20 | 0.43 |
| ▸ | GRIA4 | P48058 | 1/20 | 0.41 |
| ▸ | MTNR1B | P49286 | 2/20 | 0.40 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.39 |
| ▸ | ACACB | O00763 | 1/20 | 0.39 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.39 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.39 |
| ▸ | ACACA | Q13085 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6763719 | 0.90 | ACACB (0.47) | CA4CA12CA1CA2CA9 | |
| SCHEMBL6763752 | 0.89 | CA4 (0.45) | CA4CA12CA1CA2CA9 | |
| SCHEMBL6759350 | 0.88 | GRIA4 (0.47) | CA4CA12CA1CA2CA9 | |
| SCHEMBL6762172 | 0.85 | RAB9A (0.47) | CA4CA12CA1CA2CA9 | |
| SCHEMBL6763807 | 0.84 | ALDH1A1 (0.47) | CA4CA12CA1CA2CA9 | |
| SCHEMBL6763170 | 0.82 | GRIA4 (0.41) | CA4CA12CA1CA2CA9 | |
| SCHEMBL6573583 | 0.82 | GRIA4 (0.48) | CA4CA12CA1CA2CA9 | |
| SCHEMBL6766145 | 0.81 | GRIA4 (0.43) | CA4CA12CA1CA2CA9 | |
| SCHEMBL6765779 | 0.81 | ALDH1A1 (0.52) | CA12CA1CA2CA9GRIA4 | |
| SCHEMBL6763723 | 0.80 | GRIA4 (0.53) | CA12CA1CA2CA9GRIA4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040147612-A1 | Sulfonamide derivatives | DAVISON JOSHUA ZWICK (US) | 2004-07-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040147612-A1 | Sulfonamide derivatives | GRIN1, GRIN2A, GRIA1 | CA4 2818/4885CA12 1432/4885CA1 623/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.